PA
SLNO

Profund Advisors’s Soleno Therapeutics SLNO Stock Holding History

Profund Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,607
Closed -$1.19M – 1235
2026
Q1 		$1.19M Buy
35,607
+236
+0.7% +$9.25K 0.04% 303
2025
Q4 		$1.64M Buy
35,371
+15,532
+78% +$852K 0.05% 255
2025
Q3 		$1.34M Buy
19,839
+9,677
+95% +$717K 0.04% 267
2025
Q2 		$851K Buy
10,162
+513
+5% +$38.4K 0.03% 332
2025
Q1 		$689K Sell
9,649
-3,127
-24% -$152K 0.03% 390
2024
Q4 		$574K Buy
12,776
+1,580
+14% +$81.9K 0.02% 441
2024
Q3 		$565K Buy
11,196
+1,181
+12% +$56.5K 0.02% 489
2024
Q2 		$409K Sell
10,015
-6,059
-38% -$257K 0.02% 565
2024
Q1 		$688K Buy
16,074
+7,887
+96% +$357K 0.03% 464
2023
Q4 		$330K Buy
+8,187
New +$233K 0.01% 732

Profund Advisors's SLNO Position: Q2 2026 in Review

Profund Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 35,607 shares — an estimated $1.19M sold.

Profund Advisors first reported a position in SLNO in Q4 2023 and held it in 10 quarters. The position peaked at $1.64M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Profund Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Profund Advisors sold 35,607 Soleno Therapeutics shares in Q2 2026, an estimated $1.19M.
  • Profund Advisors first reported a position in Soleno Therapeutics in Q4 2023 and held it in 10 quarters.
  • Profund Advisors's Soleno Therapeutics position peaked at $1.64M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.